Blood markers may predict arthritis drug success

NCT ID NCT03561649

Completed Knowledge-focused Sponsor: University Hospital, Grenoble Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to find blood markers that can predict whether the drug adalimumab will successfully treat ankylosing spondylitis after 6 months. Researchers analyzed blood samples from 50 adults starting adalimumab for the first time. The goal was to create an algorithm to help doctors identify which patients are most likely to benefit from the treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPONDYLITIS, ANKYLOSING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis Spondylarthritis spondyloarthropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SPONDYLITIS, ANKYLOSING

Contacts and locations

Locations

CH de Belfort

Belfort, 90016, France
CHRU de Clermont-Ferrand

Clermont-Ferrand, 63003, France
CHU de Besançon

Besançon, 25030, France
CHU de Grenoble

Échirolles, 38434, France
CHU de Saint-Etienne

Saint-Etienne, 42055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.